User profiles for Noemi Reguart
Noemi ReguartHospital Clinic Barcelona Verified email at clinic.ub.es Cited by 20651 |
Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
…, V Calvo, A Insa, S Ponce, N Reguart… - … England Journal of …, 2023 - Mass Medical Soc
Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a
variety of solid tumors, but most patients exhibit partial or complete resistance to treatment …
variety of solid tumors, but most patients exhibit partial or complete resistance to treatment …
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
…, E Dansin, J De Castro, M Milella, N Reguart… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
…, E Carcereny, E Felip, I Bover, A Insa, N Reguart… - JAMA …, 2015 - jamanetwork.com
Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …
[HTML][HTML] Screening for epidermal growth factor receptor mutations in lung cancer
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm …
…, P Bidoli, A Favaretto, P Froesch, N Reguart… - The Lancet …, 2017 - thelancet.com
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
PD-L1 expression testing in non-small cell lung cancer
…, N Vilarińo, R Reyes, N Reguart - … Advances in Medical …, 2018 - journals.sagepub.com
In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, …
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, …
[HTML][HTML] Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
J Wolf, T Seto, JY Han, N Reguart… - … England Journal of …, 2020 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts
Epigenetic changes through altered DNA methylation have been implicated in critical aspects
of tumor progression, and have been extensively studied in a variety of cancer types. In …
of tumor progression, and have been extensively studied in a variety of cancer types. In …
[PDF][PDF] Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
…, E Caudler, Y Lo, F Baribaud, I Mikami, N Reguart… - Cancer cell, 2006 - cell.com
We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of
heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small …
heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small …